Article
Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Clinical chemistry - 1 Feb 2005
Steimer Werner, Zöpf Konstanze, von Amelunxen Silvia, Pfeiffer Herbert, Bachofer Julia, Popp Johannes, Messner Barbara, Kissling Werner, Leucht Stefan
Abstract excerpt
BACKGROUND: Amitriptyline has been replaced in many countries by alternative and more expensive drugs based on claims of improved tolerability and toxicity and despite slightly reduced efficacy. Preliminary studies indicate that adverse effects could be linked to polymorphisms of drug-metabolizing enzymes, but information on their clinical impact remains scanty and includes mainly case reports. We conducted a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.